{"id":618897,"date":"2022-09-28T22:50:01","date_gmt":"2022-09-28T22:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=618897"},"modified":"2022-09-28T22:50:01","modified_gmt":"2022-09-28T22:50:01","slug":"ovarian-cancer-market-to-register-sustainable-growth-during-the-forecast-period-202232-delveinsight-clovis-oncology-rubracarucaparib-immunogen-mirvetuximab-soravtansineimgn853-genentech","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ovarian-cancer-market-to-register-sustainable-growth-during-the-forecast-period-202232-delveinsight-clovis-oncology-rubracarucaparib-immunogen-mirvetuximab-soravtansineimgn853-genentech_618897.html","title":{"rendered":"Ovarian Cancer Market to Register Sustainable Growth During the Forecast Period (2022-32) – DelveInsight | Clovis Oncology (Rubraca\/rucaparib), ImmunoGen (Mirvetuximab soravtansine\/IMGN853), Genentech"},"content":{"rendered":"
\n
\"Ovarian<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Ovarian Cancer market size shall grow in the coming years owing to the increased Research and Development (R&D) activities in the therapeutics segment and growth in the patient pool. Pharmaceutical companies are working toward developing potential therapies for ovarian cancer to fulfill the unmet medical needs of the currently used therapeutics.<\/div>\n

Globally, about 100+ key pharma and biotech companies<\/strong> are working in the Ovarian Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/em><\/p>\n

DelveInsight’s “Ovarian Cancer Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Ovarian Cancer Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Ovarian Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Ovarian<\/p>\n

Ovarian Cancer: An Overview<\/strong><\/p>\n

Ovarian cancer is a disease that affects women and is a group of diseases that originates in the ovaries or in the related areas of the fallopian tubes and the peritoneum. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.<\/em><\/p>\n

Platinum-based chemotherapy<\/strong> (usually in combination with surgery) is the mainstay of first-line drug treatment for ovarian cancer tumors. Optimal management of advanced ovarian cancer includes histopathological diagnosis, accurate surgical staging, debulking surgery, and platinum-based chemotherapy. The combination of carboplatin and paclitaxel is commonly recognized as the standard regimen because of tolerability and activity.<\/em><\/p>\n

Despite advances in the field, most cases are diagnosed in the advanced stage, with a limited chance of being cured. Developing rational and effective screening and cancer prevention strategies for ovarian cancer, particularly high-grade serous cancer, requires a better understanding of the origin of this disease.<\/p>\n

Ovarian Cancer Market Key Facts<\/strong><\/p>\n